FDA Determines Regulatory Review Period for TRODELVY Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially announced its decision on the regulatory review period for TRODELVY, a human biological product, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).